XenoPort president departs

XenoPort President William Rieflin said he's leaving the company as of September 17th to take the CEO spot at an undisclosed private biotech company. He has been with the company for six years. XenoPort release

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."